Chikusetsusaponin IVa (Calenduloside F) is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR4 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.

Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.

Cucurbitacin E is a natural product isolated from the climbing stem of Cucumic melo L. It significantly suppresses the activity of the cyclin B1 CDC2 complex.Cucurbitacin E has prevention of neurodegeneration, it has potent anti-proliferative, antineoplas

Cucurbitacin Q1, a compound isolated from the fruit of Cucumis prophetarum, has been shown to be the pure trans component of cucurbitacin Q.

Dihydrocucurbitacin B (23,24-dihydrocucurbitacin B) is isolated from the roots of Cayaponia tayuya with anti-cancer activity.

1. Cucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. 2. Cucurbitacin IIb exhibits its anti-inflammatory activity through modula

Cucurbitacin B 2-o-α²-D-glucoside has anticancer activity.

Arvenin II is a natural product from Hemsleya amabilis.

Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase.

Cucurbitacins from Wilbrandia ebracteata have analgesic effects. Cucurbitacin S has anticancer and antiinflammatory activities.

1. Cucurbitacin IIA (Dihydrocucurbitacin Q1) can induce apoptosis and enhance autophagy , contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases. 2. Cucurbitacin IIA is a novel class of anti-cancer drug in suppression of cancer cell expansion by disrupting the actin cytoskeleton and directing the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.

Cucurbitacin D, a triterpenoid isolated from Ecballium elaterium (L.), exhibits anticancer and antitumor activity, inhibits glucose uptake and lactate production in metastatic PrC, and induces inflammasome activation independent of ERK1/2 activation. Cucurbitacin D, a novel inflammasome activator in macrophages, inhibits HepG2 cell proliferation and induces apoptosis by modulating the JAK/STAT3, PI3K/Akt/mTOR and MAPK signaling pathways, and can be used in the study of cervical cancer, leukemia, and prostate cancer.